a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announced that it has submitted a Clinical Trial Application (CTA) to initiate a Phase 1/2 clinical trial of OTOF-GT in Europe (France, Italy and Germany). On July 10th, 2023, Sensorion submitted a first CTA for OTOF-GT to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). The phase 1/2...